PURPOSE: CD44 is a multifunctional cell surface receptor with many known splice variants, some of which have been reported to play a role in tumor progression. The purpose of this study was to evaluate the prognostic significance of CD44 isoforms in early-stage, lymph node-negative invasive breast carcinoma. EXPERIMENTAL DESIGN: Immunohistochemical staining for CD44 isoforms was done on archival paraffin tissue sections of invasive breast carcinoma from a cohort of lymph node-negative patients who received no adjuvant tamoxifen or chemotherapy and who had a mean clinical follow-up period of 15 years. Immunohistochemical staining was done with antibodies to CD44s, the standard isoform of CD44, and to isoforms containing variant exon 6 (CD44v6); levels of staining were correlated with clinical outcome data. RESULTS: There was a trend towards increased disease-free survival for patients whose tumors had high anti-CD44s positivity (P = 0.05), and a significant association was observed between anti-CD44s positivity and disease-related survival (P = 0.04). Expression of CD44v6 isoforms did not correlate with clinical outcome. CONCLUSION: CD44 expression, as assessed by immunohistochemical staining with anti-CD44s, may be a favorable prognostic factor in patients with node-negative invasive breast carcinoma.
PURPOSE:CD44 is a multifunctional cell surface receptor with many known splice variants, some of which have been reported to play a role in tumor progression. The purpose of this study was to evaluate the prognostic significance of CD44 isoforms in early-stage, lymph node-negative invasive breast carcinoma. EXPERIMENTAL DESIGN: Immunohistochemical staining for CD44 isoforms was done on archival paraffin tissue sections of invasive breast carcinoma from a cohort of lymph node-negative patients who received no adjuvant tamoxifen or chemotherapy and who had a mean clinical follow-up period of 15 years. Immunohistochemical staining was done with antibodies to CD44s, the standard isoform of CD44, and to isoforms containing variant exon 6 (CD44v6); levels of staining were correlated with clinical outcome data. RESULTS: There was a trend towards increased disease-free survival for patients whose tumors had high anti-CD44s positivity (P = 0.05), and a significant association was observed between anti-CD44s positivity and disease-related survival (P = 0.04). Expression of CD44v6 isoforms did not correlate with clinical outcome. CONCLUSION:CD44 expression, as assessed by immunohistochemical staining with anti-CD44s, may be a favorable prognostic factor in patients with node-negative invasive breast carcinoma.
Authors: Elena Sanmartín; Fernando Ortiz-Martínez; Eloy Pomares-Navarro; Araceli García-Martínez; Montserrat Rodrigo-Baños; Marta García-Escolano; Leire Andrés; Enrique Lerma; Francisco I Aranda; Pascual Martínez-Peinado; José M Sempere-Ortells; Gloria Peiró Journal: Virchows Arch Date: 2016-11-24 Impact factor: 4.064
Authors: Michael J Flister; Bradley T Endres; Nathan Rudemiller; Allison B Sarkis; Stephanie Santarriaga; Ishan Roy; Angela Lemke; Aron M Geurts; Carol Moreno; Sophia Ran; Shirng-Wern Tsaih; Jeffery De Pons; Daniel F Carlson; Wenfang Tan; Scott C Fahrenkrug; Zelmira Lazarova; Jozef Lazar; Paula E North; Peter S LaViolette; Michael B Dwinell; James D Shull; Howard J Jacob Journal: Cancer Res Date: 2014-08-29 Impact factor: 12.701
Authors: Eva Verjans; Erik Noetzel; Nuran Bektas; Anke K Schütz; Hongqi Lue; Birgitt Lennartz; Arndt Hartmann; Edgar Dahl; Jürgen Bernhagen Journal: BMC Cancer Date: 2009-07-14 Impact factor: 4.430
Authors: Loris De Cecco; Valeria Musella; Silvia Veneroni; Vera Cappelletti; Italia Bongarzone; Maurizio Callari; Barbara Valeri; Marco A Pierotti; Maria Grazia Daidone Journal: BMC Cancer Date: 2009-11-24 Impact factor: 4.430
Authors: Aoife J Lowery; Nicola Miller; Amanda Devaney; Roisin E McNeill; Pamela A Davoren; Christophe Lemetre; Vladimir Benes; Sabine Schmidt; Jonathon Blake; Graham Ball; Michael J Kerin Journal: Breast Cancer Res Date: 2009-05-11 Impact factor: 6.466